MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced biologic pharmaceuticals.
According to a news release, Oxycapt was designed with a multilayer structure applied on silicon-free plastic syringe barrels, providing high breakage resistance, oxygen and vapor barrier, low protein adsorption, very low extractables, high UV barrier and pH stability.
“Since launching Oxycapt, more and more pharmaceutical companies have been interested in applying it to their biologics or regenerative medicines such as gene/cell therapies,” MGC Executive Officer of R&D Ko Kedo said in the release. “As we have looked for a strategic partner to enhance the presence of Oxycapt in the pharmaceutical industry, the partnership with BD will be an ideal solution for MGC. We believe this agreement will make it possible for customers to choose the best syringes for their drugs.”
In the partnership, BD and MGC will explore practical solutions for delivering newer biologic compounds, with both companies also aiming to advance sustainability and reduce carbon footprint throughout the collaboration.
“The biopharmaceutical industry continues to rely on PFS for the effective, reliable and consistent administration of medications,” BD Medical – Pharmaceutical Systems VP of R&D Bruno Baney said. “As our customers continue to grow their drug pipelines we are constantly exploring solutions to deliver newer compounds in robust, stable, and ready-to-administer formats. This agreement will further help us do so – as MGC’s experience in providing technical innovation in materials will serve as a strategic complement to our legacy of supporting the latest innovations in drug delivery for our customers.”
